LUPIN Financial Statement Analysis
|
||
|
The Revenues of LUPIN have increased by 20.25% YoY .
The Earnings Per Share (EPS) of LUPIN has increased by 71.08 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
LUPIN Last 5 Annual Financial Results
[BOM: 500257|NSE : LUPIN]
| Consolidated | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 |
|---|---|---|---|---|---|
| Revenues | ₹20,011 Cr | ₹16,642 Cr | ₹16,405 Cr | ₹15,163 Cr | ₹15,375 Cr |
| Expenses | ₹16,222 Cr | ₹14,921 Cr | ₹16,190 Cr | ₹12,596 Cr | ₹13,020 Cr |
| Operating Profit (Excl OI) | ₹3,789 Cr | ₹1,721 Cr | ₹215 Cr | ₹2,567 Cr | ₹2,355 Cr |
| Other Income | ₹142 Cr | ₹151 Cr | ₹214 Cr | ₹136 Cr | ₹484 Cr |
| Interest | ₹312 Cr | ₹274 Cr | ₹143 Cr | ₹141 Cr | ₹363 Cr |
| Depreciation | ₹1,197 Cr | ₹881 Cr | ₹1,659 Cr | ₹887 Cr | ₹970 Cr |
| Profit Before Tax | ₹2,422 Cr | ₹716 Cr | ₹-1,372 Cr | ₹1,676 Cr | ₹757 Cr |
| Profit After Tax | ₹1,936 Cr | ₹448 Cr | ₹-1,509 Cr | ₹1,228 Cr | ₹-400 Cr |
| Consolidated Net Profit | ₹1,914 Cr | ₹430 Cr | ₹-1,528 Cr | ₹1,217 Cr | ₹-269 Cr |
| Earnings Per Share (Rs) | ₹71.87 | ₹42.01 | ₹9.45 | ₹-33.62 | ₹26.81 |
| PAT Margin (%) | 8.89 | 6.10 | 1.57 | -5.09 | 4.34 |
| ROE(%) | 21.13 | 14.61 | 3.68 | -11.79 | 9.47 |
| ROCE(%) | 21.97 | 16.24 | 6.06 | -7.11 | 9.71 |
| Total Debt/Equity(x) | 0.30 | 0.19 | 0.34 | 0.32 | 0.35 |
Key Financials |
||
| Market Cap | : | ₹ 89,098.8 Cr |
| Revenue (TTM) | : | ₹ 23,375.9 Cr |
| Net Profit(TTM) | : | ₹ 3,722.2 Cr |
| EPS (TTM) | : | ₹ 81.5 |
| P/E (TTM) | : | 23.9 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| LUPIN | -1.6% | -4.5% | -13.3% |
| SUN PHARMACEUTICAL INDUSTRIES | 0.6% | 3.6% | -12.5% |
| DIVIS LABORATORIES | 1% | 9.4% | 8% |
| CIPLA | 0.9% | 1.2% | -0.2% |
| TORRENT PHARMACEUTICALS | 1.7% | 1% | 1% |
| DR REDDYS LABORATORIES | -0.5% | -4.2% | -6.3% |
| MANKIND PHARMA | 1.5% | -3.5% | -10.6% |
| ZYDUS LIFESCIENCES | -0.6% | -4.6% | -7% |
| AUROBINDO PHARMA | -3.1% | 0.5% | -25.3% |
LUPIN Revenues
[BOM: 500257|NSE : LUPIN]
| Y-o-Y | 20.25 % |
| 5 Yr CAGR | 6.81 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2025 | ₹20,011 Cr | 20.25 | |
| Mar2024 | ₹16,642 Cr | 1.44 | |
| Mar2023 | ₹16,405 Cr | 8.19 | |
| Mar2022 | ₹15,163 Cr | -1.38 | |
| Mar2021 | ₹15,375 Cr | - | |
LUPIN Operating Profit
[BOM: 500257|NSE : LUPIN]
| Y-o-Y | 120.22 % |
| 5 Yr CAGR | 12.63 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹3,789 Cr | 120.22 | |
| Mar2024 | ₹1,721 Cr | 699.37 | |
| Mar2023 | ₹215 Cr | -91.61 | |
| Mar2022 | ₹2,567 Cr | 9.01 | |
| Mar2021 | ₹2,355 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 83.17 % |
| 5 Yr CAGR | 5.45 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2025 | 18.94% | 83.17 | |
| Mar2024 | 10.34% | 689.31 | |
| Mar2023 | 1.31% | -92.26 | |
| Mar2022 | 16.93% | 10.51 | |
| Mar2021 | 15.32% | - | |
LUPIN Profit After Tax
[BOM: 500257|NSE : LUPIN]
| Y-o-Y | 345.15 % |
| 5 Yr CAGR | Positive |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2025 | ₹1,914 Cr | 345.15 | |
| Mar2024 | ₹430 Cr | Positive | |
| Mar2023 | ₹-1,528 Cr | Negative | |
| Mar2022 | ₹1,217 Cr | Positive | |
| Mar2021 | ₹-269 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 45.74 % |
| 5 Yr CAGR | 19.63 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2025 | 8.89 % | 45.74 | |
| Mar2024 | 6.1 % | 288.54 | |
| Mar2023 | 1.57 % | Positive | |
| Mar2022 | -5.09 % | Negative | |
| Mar2021 | 4.34 % | - | |
LUPIN Earnings Per Share (EPS)
[BOM: 500257|NSE : LUPIN]
| Y-o-Y | 71.08 % |
| 5 Yr CAGR | 27.96 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2025 | ₹72 | 71.08 | |
| Mar2024 | ₹42 | 344.55 | |
| Mar2023 | ₹9.45 | Positive | |
| Mar2022 | ₹-34 | Negative | |
| Mar2021 | ₹27 | - | |
LUPIN Return on Capital Employed (ROCE)
[BOM: 500257|NSE : LUPIN]
| Y-o-Y | 35.28 % |
| 5 Yr CAGR | 22.65 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2025 | 21.97% | 35.28 | |
| Mar2024 | 16.24% | 167.99 | |
| Mar2023 | 6.06% | Positive | |
| Mar2022 | -7.11% | Negative | |
| Mar2021 | 9.71% | - | |
LUPIN Share Price vs Sensex
| Current Share Price | : | ₹1,950.5 |
| Current MarketCap | : | ₹ 89,098.8 Cr |
| Updated EOD on | : | Oct 16,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| LUPIN | -1.6% |
-4.5% |
-13.3% |
| SENSEX | 1.6% |
2.1% |
2.6% |
LUPIN related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE LARGEMIDCAP | 4.5% | 7.2% | 8.3% |
| BSE 500 SHARIAH | 4.3% | 4.3% | 1.1% |
| BSE SENSEX NEXT 50 | 1.8% | 1.3% | -0.9% |
| BSE 100 ESG INDEX | 1.6% | 1.9% | 3.8% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY MIDCAP LIQUID 15 | 2% | 1.3% | 8.9% |
| NIFTY MIDCAP SELECT | 1.7% | 1.2% | 2.2% |
| NIFTY LOW VOLATILITY 50 | 1.7% | 0.8% | -0.3% |
| NIFTY 200 | 1.5% | 1.8% | 0.6% |
| NIFTY ALPHA LOW-VOLATILITY 30 | 1.5% | 0.8% | -10.6% |
You may also like the below Video Courses
FAQ about LUPIN Financials
How the annual revenues of LUPIN have changed ?
The Revenues of LUPIN have increased by 20.25% YoY .
How the Earnings per Share (EPS) of LUPIN have changed?
The Earnings Per Share (EPS) of LUPIN has increased by 71.08 % YoY .
Check out Intrinsic Value of Peers of LUPIN
Compare Stock Analytics of Peers of LUPIN
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
